Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
TAORMINA is an international, multicentre, randomised phase 3 trial for patients with oligometastatic breast cancer (OMBC) that will be allocated to combined stereotactic ablative radiotherapy (SABR) + systemic therapy (investigational arm) versus systemic therapy alone (control arm) as 1st line therapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rak piersi z ograniczoną liczbą przerzutów.
- •Pacjenci w wieku 18 lat lub starsi.
- •1 do 5 przerzutów w maksymalnie dwóch różnych miejscach w ciele.
- •Pacjentki, które już rozpoczęły leczenie ogólne, mogą wziąć udział, jeśli choroba jest stabilna.
- •Stan ogólny pacjentki dobry (nie jest zbyt osłabiona chorobą).
✗ Disqualifies
- •Pacjentki, które otrzymały więcej niż jedno leczenie ogólne w związku z rozsianym rakiem piersi.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 21, 2022
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Sahlgrenska University Hospital
Gothenburg, Sweden
Trial contact
Katarzyna Kulbacka-Ortiz, CTO
Annika Baan
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.